Sakti Chakrabarti, MD

Articles

Ongoing Research in GI Cancers

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.

Building Upon Approved Combination Regimens in Unresectable HCC

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.

Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.

Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.

Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.

The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

October 25th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.

Neoadjuvant Immunotherapy in Mismatch Repair–Deficient, Early-Stage Colorectal Cancer: The Plot Thickens

February 8th 2023

For decades, resection of the primary tumor, either up front or after neoadjuvant therapy, has remained the standard of care for patients with early-stage (stage I-III) colorectal cancer. Recently, a plethora of data have been published that might change the current surgery-centered paradigm.

Drawing Actionable Information From the Blood in Advanced Biliary Tract Cancer

March 17th 2021

A major barrier to routine genomic profiling of tumors in patients with biliary tract cancer is the lack of adequate tumor tissue in the biopsy samples; the analysis of circulating tumor DNA present in the plasma, is emerging as a promising alternative.

ctDNA-Guided MRD Assessment Enters New Horizon in Colon Cancer

February 15th 2021

Finding a reliable biomarker for minimal residual disease assessment is needed and circulating tumor DNA has shown incredible promise in colon cancer.